Analyst Reco. Immunome, Inc.

Equities

IMNM

US45257U1088

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-06 pm EDT			5-day change	1st Jan Change
15.46 ^USD	-1.84%		+11.87%	+44.49%

May. 02	Immunome, Inc. Appoints Kinney Horn as Chief Business Officer	CI
Apr. 30	JPMorgan Starts Immunome With Overweight Rating, $24 Price Target	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Starts Immunome With Overweight Rating, $24 Price Target	Apr. 30	MT
Guggenheim Starts Immunome With Buy Rating, $35 Price Target	Apr. 15	MT
Wedbush Adjusts Immunome's Price Target to $33 From $27, Maintains Outperform Rating	Apr. 01	MT
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating	Feb. 07	MT
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating	Jan. 23	MT
Immunome Shares Rise After Wedbush Starts Coverage With outperform Rating	Dec. 19	MT
Wedbush Starts Immunome With Outperform Rating, $12 Price Target; Has Positive View for Early-Stage Pipeline of Targeted Cancer Therapies	Dec. 19	MT
Chardan Cuts Price Target on Immunome to $8 From $9, Maintains Buy Rating	23-03-17	MT
Cantor Fitzgerald Initiates Immunome's Coverage With Overweight Rating, Sets Price Target at $8	22-09-27	MT
Chardan Adjusts Immunome's Price Target to $9 From $16, Citing IMM-BCP-01 Launch Expectations, Stock Dilution From Future Capital Raises; Buy Rating Kept	22-05-13	MT
Cantor Fitzgerald Starts Immunome at Overweight with $35 Price Target	21-10-29	MT
IMMUNOME : Chardan Adjusts Price Target on Immunome to $21 From $18 on Q2 Update, Maintains Buy Rating	21-08-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW